×
About 5 results

Ofatumumab Impresses in MS; Competition for Ocrelizumab Soon?
https://www.staging.medscape.com/viewarticle/918478

Sep 15th, 2019 - STOCKHOLM ― A new B cell–depleting anti-CD20 monoclonal antibody has shown impressive results in two phase 3 studies in relapse-remitting multiple sclerosis (RRMS). Ofatumumab (Novartis) yielded a reduction in relapse rates of more than 50%, a reduction in disability progression of more than 30%, and a reduction in gadolinium-enhancing T1 lesions of more than 90% in comparison with teriflunomid...

Ofatumumab Impresses in MS; Competition for Ocrelizumab Soon?
https://www.medscape.com/viewarticle/918478

Sep 15th, 2019 - STOCKHOLM ― A new B cell–depleting anti-CD20 monoclonal antibody has shown impressive results in two phase 3 studies in relapse-remitting multiple sclerosis (RRMS). Ofatumumab (Novartis) yielded a reduction in relapse rates of more than 50%, a reduction in disability progression of more than 30%, and a reduction in gadolinium-enhancing T1 lesions of more than 90% in comparison with teriflunomid...

APEX, STORM, and more
https://www.ashclinicalnews.org/news/august-2015-apex-storm-and-more/

Aug 1st, 2015

Evictions Loom for Poor, Elderly as U.S. Government Shutdown Drags on
https://emedicine.medscape.com/viewarticle/907830

NEW YORK (Thomson Reuters Foundation) - A growing number of poor, elderly and disabled people face eviction from their homes as federal housing assistance dries up under the U.S. government shutdown, experts said. The U.S. Department of Housing and Urban Development (HUD) provides housing assistance but is mostly closed under the partial shutdown. "For families and communities that rely on HUD ...

Ofatumumab Impresses in MS; Competition for Ocrelizumab Soon?
https://emedicine.medscape.com/viewarticle/918478

STOCKHOLM ― A new B cell–depleting anti-CD20 monoclonal antibody has shown impressive results in two phase 3 studies in relapse-remitting multiple sclerosis (RRMS). Ofatumumab (Novartis) yielded a reduction in relapse rates of more than 50%, a reduction in disability progression of more than 30%, and a reduction in gadolinium-enhancing T1 lesions of more than 90% in comparison with teriflunomid...